CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to EWTX

Sevasemten 10 mg

Phase 2
Edgewise Therapeutics, Inc. (EWTX)

Phase 2

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History
Sep '26
EWTXPhase 2
Positive

Sevasemten 10 mg Phase 2 Est. Readout

Sevasemten 10 mg
Sep 2026~
CT.gov
Competitive Landscape

0 competitors in Becker Muscular Dystrophy

View Full Landscape
Drug Information

Target Indication

Becker Muscular Dystrophy

Clinical Trial

NCT05291091

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.